Article Tools/Herramientas de artículos
+ Larger Font/Fuente más grande | - Smaller Font/Fuente más pequeña






Technology News Covid 19 Moderna Must Fulfil Its Promise To Share Technology To Ensure Covid 19 Vaccine Breakthrough Is Not Limited To Rich Countries Amnesty International

Search Related Content

Sorry, Your Requested Page Was Not Found. Greetings! We apologize for the inconvenience, but the page, Technology News Covid 19 Moderna Must Fulfil Its Promise To Share Technology To Ensure Covid 19 Vaccine Breakthrough Is Not Limited To Rich Countries Amnesty International is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3-18 months after their creation date. We prefer to keep content fresh and current, rather than holding onto outdated news. Thanks for visiting today.
Search RobinsPost News & Noticias


Technology News Covid 19 Moderna Must Fulfil Its Promise To Share Technology To Ensure Covid 19 Vaccine Breakthrough Is Not Limited To Rich Countries Amnesty International | RobinsPost News & Noticias

How much protection does the COVID-19 vaccine offer? How vaccinated people should approach seeing others


On December 18, a San Diego emergency room nurse was given a shot of the COVID-19 vaccine. A week later, he tested positive for the virus, CNN affiliate KGTV reported. Stories like this will become ... Read More

Combo flu and COVID-19 shot shows promise in new Moderna study


Moderna conducted a study to test a combination COVID-19 and flu shot. Researchers tested the shot on 8,000 adults. The pharmaceutical and biotechnology company is targeting 2026 for approval of the ... Read More

Moderna's new COVID-19 vaccine mNexspike approved by FDA, but there's a limit on who can use it


The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement for the company's existing shot, but a second option. The new vaccine, ... Read More

Moderna settles Alnylam patent lawsuits over COVID vaccine technology


Sept 18 (Reuters) - Moderna (MRNA.O), opens new tab has settled related lawsuits that accused it of misusing Alnylam Pharmaceuticals' (ALNY.O), opens new tab patented technology in its COVID-19 ... Read More

Moderna Provides Update on BLA Submission for Combination Vaccine Against Influenza and COVID-19


CAMBRIDGE, MA / ACCESS Newswire / May 21, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced that in consultation with the U.S. Food and Drug Administration (FDA), the Company has voluntarily ... Read More

FDA approves Moderna's new lower-dose COVID-19 vaccine


The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement for the company’s existing shot, but a second option. The new vaccine, ... Read More

A new COVID-19 variant, vaccine changes: What to know in 2025


Like it or not, COVID-19 is still a public health issue five years after the start of the pandemic flipped the nation, and the world, on its head. Here is a brief recap of the status of COVID cases, ... Read More

Moderna wins FDA approval for its new COVID-19 vaccine


Federal health agencies no longer recommend COVID-19 vaccination for healthy children and pregnant women, but older adults now have a new weapon against the virus. Moderna said it has received ... Read More

Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans


Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data ... Read More

FDA approves Moderna’s lower-dose COVID-19 vaccine for some


We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The new low-dose vaccine is one-fifth the size of ... Read More


Blow Us A Whistle


Comments (Whistles) Designed By Disqus